- Scribe records upsized $129M IPO to bankroll lipid-lowering genetic medsIn vivo gene editing outfit Scribe Therapeutics has priced its IPO at $128.7 million, surpassing the $96 million goal set out earlier this week.Fierce Biotech · 1d ago↗ source
- This Week at FDA: Diamantas touts onshoring efforts, grants for DHTs, and more<p>Welcome to another installment of This Week at FDA, your weekly source for updates – big and small – on FDA, drug, and medical device regulation, and what we’re reading from around the web. This…raps · 1d ago↗ source
- FDA advisory committee backs two more peptides, rejects one for compounding list<p>By the end of a two-day meeting that concluded Friday afternoon, an advisory committee to the US Food and Drug Administration (FDA) voted in favor of adding six of the seven peptides it was task…